XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Cash flows from operating activities:      
Net loss $ (30,469,871) $ (40,649,317)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 424,473 707,378  
Amortization of intangible assets 0 82,083  
Amortization of operating lease right-of-use assets 335,257 362,664  
Non-cash stock-based compensation 2,525,433 3,809,003  
Non-cash interest on senior convertible notes (355,654) (219,999)  
Amortization of discounts on investments (684,651) (1,159,083)  
Loss on sales of short-term investments 691,168 2,425,676  
Loss on disposal of fixed assets 0 334,297  
Loss (gain) on equity investment in affiliated entity 126,018 (616,639)  
Net unrealized gain on available-for-sale equity securities (500,877) (3,218,215)  
Changes in operating assets and liabilities:      
Accounts receivable, including from affiliated entities (145,854) 6,703,110  
Prepaid expenses and other current assets, including from affiliated entities 1,897,016 39,324,542  
Other assets 0 31,527  
Accounts payable and accrued expenses, including due to affiliated entities (3,160,238) (40,737,879)  
Accrued clinical trial expenses 657,104 (4,798,227)  
Operating lease right-of-use assets and liabilities, net (11,791) (693,691)  
Grant funding liability, including from affiliated entity (87,489) 1,648,292  
Net cash used in operating activities (28,759,956) (36,664,478)  
Cash flows from investing activities:      
Purchases of investments (9,751,047) (80,431,174)  
Proceeds from sale or maturity of investments 55,169,260 93,657,050  
Purchases of capital assets (35,578) (296,983)  
Proceeds from sale of capital assets 0 6,071,000  
Net cash provided by investing activities 45,382,635 18,999,893  
Cash flows from financing activities:      
Repayment of convertible senior notes (16,415,000) 0  
Proceeds from issuance of common stock, net of issuance costs 5,225,133 0 $ 5,500,000
Taxes paid related to net share settlement of equity awards (174,248) (424,704)  
Net cash used in financing activities (11,364,115) (424,704)  
Effect of exchange rate changes on cash and cash equivalents 32,403 (1,918)  
Increase (Decrease) in cash and cash equivalents 5,290,967 (18,091,207)  
Cash and cash equivalents, beginning of period 14,310,862 46,329,359 46,329,359
Cash and cash equivalents, end of period 19,601,829 28,238,152 $ 14,310,862
Supplemental disclosures:      
Amounts accrued for purchases of fixed assets 442,976 0  
Interest paid 533,487 533,187  
Issuance of common stock as part of litigation settlement $ 0 $ 14,000,000